581813-19-6 Usage
Description
(3-Bromo-4-(trifluoromethyl)phenyl)methanamine, with the molecular formula C8H6BrF3N, is a chemical compound that is a derivative of phenylmethylamine. It features a bromine atom and a trifluoromethyl group attached to the phenyl ring, giving it unique properties and potential applications in various fields.
Uses
Used in Pharmaceutical and Agrochemical Industries:
(3-Bromo-4-(trifluoromethyl)phenyl)methanamine is utilized as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows it to be a key component in the development of new drugs and agricultural products.
Used as a Reagent in Organic Synthesis:
(3-broMo-4-(trifluoroMethyl)phenyl)MethanaMine also serves as a reagent in organic synthesis, where it can be used to facilitate chemical reactions and help in the formation of desired products.
Used as a Starting Material for Chemical Compound Preparation:
(3-Bromo-4-(trifluoromethyl)phenyl)methanamine is employed as a starting material for the preparation of other chemical compounds, making it a versatile component in the field of chemistry.
Used in Medicinal Chemistry and Drug Discovery:
Due to its pharmacological properties, (3-Bromo-4-(trifluoromethyl)phenyl)methanamine has potential applications in the field of medicinal chemistry and drug discovery, where it can contribute to the development of new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 581813-19-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,1,8,1 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 581813-19:
(8*5)+(7*8)+(6*1)+(5*8)+(4*1)+(3*3)+(2*1)+(1*9)=166
166 % 10 = 6
So 581813-19-6 is a valid CAS Registry Number.
581813-19-6Relevant articles and documents
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
-
, (2008/06/13)
Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
